significance of ruxolitinib and unmet needs in mf
Published 6 years ago • 107 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
2:24
addressing unmet needs in the management of myelofibrosis
-
2:14
unmet needs in myelofibrosis
-
1:02
dr. kremyanskaya on unmet needs in myelofibrosis
-
1:30
the importance of intervention in chronic phase myelofibrosis
-
3:30
unmet needs in mf: managing anemia & improving the efficacy of first and second-line treatments
-
1:05
the role of ruxolitinib in myeloproliferative neoplasms
-
2:54
unmet needs in myelofibrosis and future outlooks
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
2:08
a study exploring sotatercept and ruxolitinib in mpn-associated myelofibrosis and anemia
-
4:45
myelofibrosis: long-term survival data and ruxolitinib use
-
4:43
the role of ruxolitinib in treating polycythemia vera
-
4:37
the use of ruxolitinib in mpn
-
0:31
exploring the benefits of ruxolitinib in second-line polycythemia vera
-
1:30
addressing unmet needs in myelofibrosis: alleviating anemia
-
1:44
controlling symptoms in patients with mf treated with hypomethylating agents
-
6:15
comfort trials: initiating therapy for myelofibrosis
-
1:52
dr. john mascarenhas on the comfort-i/ii studies for ruxolitinib in myelofibrosis
-
5:31
case 1: ruxolitinib treatment for myelofibrosis
-
1:40
considering fedratinib or ruxolitinib in the frontline setting for treatment of myelofibrosis